InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
0.00%
)
US TECH 100
19,323.20
(
-0.06%
)
Dow Jones
42,025.19
(
0.00%
)
Brent Oil
73.85
(
-0.64%
)
Bitcoin
63,218.53
(
0.43%
)
Post# of 11554
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

StocksDiva

Send PM Follow Ignore
Followers 378
Posts 20728
Boards Moderated 2
Alias Born 03/28/2010

StocksDiva

Re: StocksDiva post# 11456

Tuesday, 05/27/2014 8:45:49 AM

Tuesday, May 27, 2014 8:45:49 AM

Post# of 11554
NVGN Novogen announces milestone with its super-benzopyran (:SBP) drug program; extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers (NVGN) : NVGN announced that it has achieved a key milestone with its super-benzopyran (:SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers.


StocksDiva Bio Bin board

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up